Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) Novartis Ongoing Fingolimod 4 TY720DAE01 King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah)
Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients KAIMRC Ongoing Esmoprozol 4 RC15/079 King Abdulaziz Medical City NG (Riyadh)
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center Ongoing ombitasvir \ paritaprevir \ ritonavir 3 Version 1.3.1 King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah)
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis Novartis Ongoing ofatumumab 3 COMB157G2301 King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan Sanofi Terminated Lixisenatide 3 LPS14410 King Khalid University Hospital (Riyadh)
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation" Novartis Ongoing deferasirox 2 CICL670FIC05 King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh)
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease. Dilaforette AB Ongoing Sevuparin 2 TVOC01 King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant ICR Group - International Cancer Research group Ongoing palbociclib fulvestrant 3 ICRG 1201 King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)
A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF USING TOCILIZUMAB (TCZ) FOR CONFIRMED RHEUMATOID ARTHRITIS (RA) PATIENTS IN CLINICAL PRACTICE Roche Ongoing tocilizumab 4 ML299336 King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh)
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age Shire Human Genetic Therapies, Inc Ongoing Elaprase 4 SHPELA401 King Faisal Specialist Hospital and Research Center (Riyadh)
View 561 - 570 From 741